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Abstract
Very-long-chain acyl-CoA dehydrogenase deficiency is the second most common 
disorder of fatty acid oxidation in the USA, with an incidence of 1:25,000-1:100,000 
newborns (Tucci, Floegel, Beermann, Behringer, Spiekerkoetter, 2017, pg. 196). The 
current dietary therapeutic strategies are designed to avoid long chain fatty acids, 
instead providing carbohydrates and medium chain triglycerides as an energy source. 
Despite the controlled and biochemically balanced diet, it has a limited success in 
treatment of clinical symptoms and metabolic decompensations in VLCAD affected 
individuals. It has been proposed that defect in long chain fatty acids catabolic pathway 
leads to the severe energy deficiency, that primary reflected by depletion of citric acid 
cycle (TCA) intermediates. This research study explores the effect of dodecanedioic 
acid (DODA) as potential anaplerotic reagent in fibroblasts from healthy and 
documented VLCAD individuals. To investigate effect of DODA cells were depleted 
from glucose and supplemented with L-Carnitine and palmitic acid. Cells were treated 
for 16 hours with 50μM of DODA. Then, we analyzed levels of acylcarnitine TCA 
intermediates, fatty acids and glucose.
We found accumulation of long chain acyl carnitines (C14 and C16) in VLCAD 
fibroblasts which is consistent with the VLCAD presentation in human. We also 
observed increase in TCA intermediates levels, post DODA treatment indicating 
DODA anaplerotic effect, however, glucose levels were not rescued post DODA 
treatment. In conclusion, our data support that hypothesis that DODA can replenish 
TCA and thus it represents a potential anaplerotic therapy for VLCAD disorder.
Further studies in vitro are warranted to further explore DODA effects on energy 
metabolism.
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